Frontage Holdings Corp. 1521
HKEX · Çin Hong Kong ÖİB · Sağlık Teknolojisi
HKD 1,180,00 (%0,00)
Piyasa kapalı· · HKD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · HKD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, is pleased to welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services. Dr. Prakash is internationally recognized for his scientific leadership in drug metabolism and pharmacokinetics (DMPK), clinical pharmacology, biotransformation, bioanalysis, and translational ADME sciences. Over his 40‑year career, he has made significant contributions to the mechanistic understanding of drug disposition, metabolic pathways
As Asian markets navigate the complexities of rising energy costs and inflationary pressures, investors are increasingly looking for opportunities that offer growth potential at lower entry points. Penny stocks, though an older term, remain relevant today as they often represent smaller or newer companies with untapped potential. By identifying those with strong financials and a promising growth path, investors can uncover valuable opportunities in this segment of the market.
Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. ("Teddy Lab"), a leading clinical research laboratory service provider in China. The acquisition aims to enhance Frontage's global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.